This is a website for healthcare professionals.
Conference
ACR Convergence 2024
American College of Rheumatology
Washington, DC
November 14, 2024 | November 19, 2024
Booth # 3729
Visit Us at Booth 3729
Exagen is thrilled to be participating in ACR Convergence 2024, an annual meeting hosted by the American College of Rheumatology (ACR) scheduled for November 9 - 14 in Washington, DC. This conference features a wide range of activities including educational sessions, scientific presentations, networking opportunities, and exhibits. Not only will Exagen be exhibiting at Booth #3729, but we will be disseminating new research via 5 posters and a presentation at the Innovation Theatre. If you are attending, stop by our booth or reach out to us to schedule a meeting with an Exagen representative to learn more about our latest products, services and technologies.
Saturday, November 16, 2024
|
10:00 AM - 5:00 PM EDT
Sunday, November 17, 2024
|
10:00 AM - 5:00 PM EDT
Monday, November 18, 2024
|
10:00 AM - 2:30 PM EDT
Schedule a Meeting
Chat directly with Exagen staff who will be available to answer any questions that you have about AVISE tests and discuss how we can help support you through the patient care journey.
Schedule a Meeting
Innovation Theater
Real-World Solutions
The Role of Novel Biomarkers in Diagnosing SLE and RA
Back to Events
Innovation Theater, Theater B
Sunday, November 17, 2024
Booth # 3729
How can you help your ANA+ patients who also have undifferentiated arthritis quickly find a diagnosis? Conventional biomarker tests available today can still leave some patients without the answers needed to end their diagnostic journey.
Join Dr. Andrew Concoff, Rheumatologist and Chief Innovation Officer, Exagen Inc., for a presentation and live Q and A. They will share their research into novel biomarkers that will become tools you can use to confidently diagnose this challenging patient population.
In this session you will gain:
- A greater understanding of emergent biomarkers in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
- Insights into how T Cell biomarkers could be used to confidently diagnose patients who do not clearly present as SLE using conventional biomarkers
- Awareness around a new panel of novel biomarkers intended to close the seronegative gap for RA
Andrew Concoff, MD, FACR
Chief Innovation Officer
Vasileios Kyttaris, MD, PhD, FACR
Internist and Rheumatologist
Poster Presentations
Multi-Center Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Markers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
In collaboration with Beth Israel Deaconess Medical Center and AHN
Poster number
Date
Time
Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
In collaboration with AHN
Poster number
Date
Time
Anti-RA33 Autoantibodies are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
In collaboration with AHN and Thermo Scientific
Poster number
Date
Time
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
In collaboration with AHN, Werfen, and Thermo Scientific
Poster number
Date
Time
A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
In collaboration with Andrea Fava and Michelle Petri @ Johns Hopkins University
Poster number
Date
Time